Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Weekly channel feed
FDA raises questions about Lilly's Alzheimer's drug; Adcomm votes against MDMA therapy; Inside Walmart Health's challenges; and more
11 months ago
Merck’s $3B return to eye disease; J&J’s $1.25B tuck-in; Keytruda challenger steals #ASCO24 show; and more
11 months ago
Pfizer's $1.5B cuts; Biogen's $1.15B buyout; AstraZeneca's $80B ambition; RNA startup merger; and more
Last year
Mega startup watch; Interview with Siddhartha Mukherjee; Tracking Wegovy’s long-term effects; Biogen’s ALS flop; and more
Last year
Top stories from cell/gene therapy confab; 2032 deadline to decouple; Patient death in Pfizer trial; and more
Last year
Novartis’ radiopharma gambit; Weight loss battle plays out; Spark co-founder’s new startup; Q1 earnings highlights; and more
Last year
Bristol Myers eyes major cuts; That $1B AI startup; Pharma reacts to China bill; Q1 earnings highlights; and more
Last year
Nvidia's biotech moment; Regeneron launches venture arm; New GLP-1 player enters; Sanofi rejigs cancer pact, vaccine ops; and more
Last year
Vertex's $4.9B bet; Layoffs at Novartis, Genentech, Sanofi; Star founders unveil new startups; and more
Last year
US-China tensions persist; Genmab's $1.8B ADC bet; New obesity startup in town; ALS drug withdrawal; and more
Last year
Return of the megarounds; Nvidia’s AI pitch to biotech; Bayer’s shakeup reaches the top; AstraZeneca buys into radiopharma; and more
Last year
WuXi fallout reverberates; Pharma's top R&D spenders; Lilly teams up with Amazon; Historic NASH approval; and more
Last year
Amylyx’s ALS disappointment; Lilly's Alzheimer's delay; Bayer stays put; Novo Nordisk's GLP-1 streak; and more
Last year
Eli Lilly’s Alzheimer’s trek; Novo Nordisk puts down US roots; Sarepta and gene therapy accelerated approvals; and more
Last year
AbbVie’s next CEO; $100B club refresh; Top 100 VCs, 2023; More hope for CAR-T in autoimmune; and more
Last year
Gilead's $4.3B liver bet; WuXi under fire; Exscientia CEO’s ouster; Late Friday cell therapy approval; and more
Last year
Novo Holdings’ $16.5B bid for Catalent; Novartis’ $2.9B bolt-on; Endpoints Slack interview with John Evans; and more
Last year
End of Aduhelm’s road; Janet Woodcock exit interview; Stuart Schreiber's $500M experiment; Vertex's pain breakthrough; and more
Last year
Sanofi's $1.7B rare disease gambit; CAR-T boxed warning saga; New biotechs on Nasdaq; A seller's market for M&A?; and more
Last year
Bayer rolls out big changes; 2024's biotech IPO queue; Dupixent's 'next big thing'; 23andMe's struggle with dual identity; and more
Last year
Four buyouts (and one rumor that didn’t materialize); Isomorphic Labs' first pharma deals; A CAR-T IPO; #JPM24 highlights; and more
Last year
Roche leads pre-JPM deal spree; Roger Perlmutter’s new pharma force; Inside Sage’s big triumph and failure; Late Friday IPO filings; All new drugs in 2023; and more
Last year
Pfizer's turmoil; FTC's new target; Aviv Regev Q&A; AstraZeneca's vaccine gambit; Best of #ASH23; and more
Last year
AbbVie’s $8.7B neuro gambit; Landmark sickle cell approvals; Roche buys a GLP-1 company; Endpoints 100 biotech survey; and more
Last year
First page
Previous page
1
2
3
4
5
6
Next page
Last page
